Abstract
We report on 11 patients with HIV infection and visceral leishmaniasis and who were treated with meglumine antimoniate plus allopurinol for 3 weeks (six patients) or 4 weeks (five patients). Clinical and parasitological cures were achieved in four of the five patients treated for 4 weeks and in one of the six patients treated for 3 weeks. Only one patient developed a severe maculopapular rash. Allopurinol plus meglumine antimoniate was found to be a safe combination of drugs for the treatment of visceral leishmaniasis in patients infected with HIV. The optimal length of this treatment is unknown but a course of at least 4 weeks' duration would appear to be necessary for obtaining parasitological cure in most cases.
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy*
-
Acquired Immunodeficiency Syndrome / complications
-
Administration, Oral
-
Adult
-
Allopurinol / administration & dosage
-
Allopurinol / therapeutic use*
-
Antiprotozoal Agents / administration & dosage
-
Antiprotozoal Agents / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
HIV Infections / complications*
-
Humans
-
Injections, Intramuscular
-
Leishmaniasis, Visceral / drug therapy*
-
Male
-
Meglumine / administration & dosage
-
Meglumine / therapeutic use*
-
Meglumine Antimoniate
-
Organometallic Compounds / administration & dosage
-
Organometallic Compounds / therapeutic use*
-
Pilot Projects
Substances
-
Antiprotozoal Agents
-
Organometallic Compounds
-
Allopurinol
-
Meglumine
-
Meglumine Antimoniate